menu
    • menu
    [{"orgOrder":0,"company":"Wellbeing Digital Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Wellbeing Digital Sciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Wellbeing Digital Sciences \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Wellbeing Digital Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Wellbeing Digital Sciences","sponsor":"Nova Mentis Life Science","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Agreement","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Wellbeing Digital Sciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Wellbeing Digital Sciences \/ Nova Mentis Life Science","highestDevelopmentStatusID":"5","companyTruncated":"Wellbeing Digital Sciences \/ Nova Mentis Life Science"},{"orgOrder":0,"company":"Fibrocor Therapeutics","sponsor":"McQuade Center","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"CANADA","productType":"Other Large Molecule","year":"2024","type":"Collaboration","leadProduct":"FIB918","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Fibrocor Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fibrocor Therapeutics \/ McQuade Center","highestDevelopmentStatusID":"5","companyTruncated":"Fibrocor Therapeutics \/ McQuade Center"}]

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Satellos Bioscience

                            Canada arrow
                            IFT FIRST
                            Not Confirmed

                            Satellos Bioscience

                            Canada arrow
                            IFT FIRST
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SAT-3247

                            Therapeutic Area : Genetic Disease

                            Study Phase : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Satellos Submits Filing for Phase 1 Trial with SAT-3247

                            Details : SAT-3247 is a once-daily, oral small molecule, AAK1 inhibitor that targets the root cause of muscle loss in degenerative diseases. It is currently in investigation for duchenne muscular dystrophy.

                            Product Name : SAT-3247

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            November 07, 2024

                            Lead Product(s) : SAT-3247

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Satellos Bioscience

                            Canada arrow
                            IFT FIRST
                            Not Confirmed

                            Satellos Bioscience

                            Canada arrow
                            IFT FIRST
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SAT-3247

                            Therapeutic Area : Genetic Disease

                            Study Phase : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Satellos Announces Filing to Start Phase 1 Trial with SAT-3247

                            Details : SAT-3247 is a once-daily, oral small molecule, AAK1 inhibitor that targets the root cause of muscle loss in degenerative diseases. It is currently in investigation for duchenne muscular dystrophy.

                            Product Name : SAT-3247

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            August 19, 2024

                            Lead Product(s) : SAT-3247

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Satellos Bioscience

                            Canada arrow
                            IFT FIRST
                            Not Confirmed

                            Satellos Bioscience

                            Canada arrow
                            IFT FIRST
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SAT-3247

                            Therapeutic Area : Genetic Disease

                            Study Phase : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Satellos Receives FDA Rare Pediatric Designation for SAT-3247 in Duchenne Dystrophy

                            Details : SAT-3247 is a once-daily, oral small molecule, AAK1 inhibitor that targets the root cause of muscle loss in degenerative diseases. It is currently in investigation for duchenne muscular dystrophy.

                            Product Name : SAT-3247

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            August 08, 2024

                            Lead Product(s) : SAT-3247

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Satellos Bioscience

                            Canada arrow
                            IFT FIRST
                            Not Confirmed

                            Satellos Bioscience

                            Canada arrow
                            IFT FIRST
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SAT-3247

                            Therapeutic Area : Genetic Disease

                            Study Phase : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Satellos Forms Clinical Advisory Board for SAT-3247 in Duchenne Muscular Dystrophy

                            Details : SAT-3247 is a small molecule designed to inhibit AAK1, a protein kinase member of the notch pathway. It is being developed for the treatment of duchenne muscular dystrophy.

                            Product Name : SAT-3247

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            May 28, 2024

                            Lead Product(s) : SAT-3247

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Fibrocor Therapeutics

                            Canada arrow
                            IFT FIRST
                            Not Confirmed

                            Fibrocor Therapeutics

                            Canada arrow
                            IFT FIRST
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : FIB918

                            Therapeutic Area : Genetic Disease

                            Study Phase : IND Enabling

                            Sponsor : McQuade Center

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Fibrocor Partners with McQuade Center for R&D to Advance Alport Syndrome Program

                            Details : The collaboration aims to support the clinical development of Fibrocor's FIB918, a monoclonal antibody. Currently, it is being evaluated in the IND-enabling phase for the treatment of Alport Syndrome.

                            Product Name : FIB918

                            Product Type : Other Large Molecule

                            Upfront Cash : Undisclosed

                            May 03, 2024

                            Lead Product(s) : FIB918

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : IND Enabling

                            Sponsor : McQuade Center

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Satellos Bioscience

                            Canada arrow
                            IFT FIRST
                            Not Confirmed

                            Satellos Bioscience

                            Canada arrow
                            IFT FIRST
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SAT-3247

                            Therapeutic Area : Genetic Disease

                            Study Phase : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Satellos Presents Data Showing Muscle Repair from SAT-3247 in Canine Model of DMD

                            Details : SAT-3247 is a once-daily, oral small molecule, AAK1 inhibitor that targets the root cause of muscle loss in degenerative diseases. It is currently in investigation for duchenne muscular dystrophy.

                            Product Name : SAT-3247

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            February 07, 2024

                            Lead Product(s) : SAT-3247

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Satellos Bioscience

                            Canada arrow
                            IFT FIRST
                            Not Confirmed

                            Satellos Bioscience

                            Canada arrow
                            IFT FIRST
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SAT-3247

                            Therapeutic Area : Genetic Disease

                            Study Phase : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Satellos Discloses Drug Target and Provides Development Update on Duchenne Muscular Dystrophy Program

                            Details : SAT-3247 as lead drug candidate that target AAK1, a protein kinase, which is investigated for the treatment of Duchenne Muscular Dystrophy. The patent applications for its drug target and drug development candidates, and remains on track to initiate clin...

                            Product Name : SAT-3247

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            November 14, 2023

                            Lead Product(s) : SAT-3247

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            KGK Science

                            Canada arrow
                            IFT FIRST
                            Not Confirmed

                            KGK Science

                            Canada arrow
                            IFT FIRST
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Psilocybine

                            Therapeutic Area : Genetic Disease

                            Study Phase : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Wellbeing Subsidiary KGK Science Begins Recruitment in First-of-its-Kind Health Canada Approved Psilocybin Tri...

                            Details : NM-1001 (psilocybin) reacts agonistically with serotonin (5-hydroxytryptamine) type 2A (5-HT2A) receptors to produce a “mystical-like” hallucinatory effect due to induced frontal hyper-frontality, which in turn mediates its anti-depressant and anti-a...

                            Product Name : NM-1001

                            Product Type : Controlled Substance

                            Upfront Cash : Inapplicable

                            April 18, 2023

                            Lead Product(s) : Psilocybine

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Wellbeing Digital Sciences

                            Canada arrow
                            IFT FIRST
                            Not Confirmed

                            Wellbeing Digital Sciences

                            Canada arrow
                            IFT FIRST
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Psilocybine

                            Therapeutic Area : Genetic Disease

                            Study Phase : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Wellbeing Subsidiary KGK Science Submits CTA for Phase IIA Clinical Trial

                            Details : Nova Mentis has completed production of pharmaceutical grade cGMP synthetic psilocybin 1.5 mg microdose capsules that will be used to advance the necessary research and development steps needed for successful drug regulatory approval and future commercia...

                            Product Name : NM-1001

                            Product Type : Controlled Substance

                            Upfront Cash : Inapplicable

                            November 30, 2022

                            Lead Product(s) : Psilocybine

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth